These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
147 related articles for article (PubMed ID: 6220671)
21. In vitro activity of ciprofloxacin (Bay o 9867). Fass RJ Antimicrob Agents Chemother; 1983 Oct; 24(4):568-74. PubMed ID: 6228192 [TBL] [Abstract][Full Text] [Related]
22. In vitro antibacterial activity of AM-715, a new nalidixic acid analog. Ito A; Hirai K; Inoue M; Koga H; Suzue S; Irikura T; Mitsuhashi S Antimicrob Agents Chemother; 1980 Feb; 17(2):103-8. PubMed ID: 6446258 [TBL] [Abstract][Full Text] [Related]
23. In vitro and in vivo antibacterial activity of AT-2266. Kouno K; Inoue M; Mitsuhashi S Antimicrob Agents Chemother; 1983 Jul; 24(1):78-84. PubMed ID: 6226242 [TBL] [Abstract][Full Text] [Related]
24. Norfloxacin: in vitro activity compared with that of seven other antibacterial agents against urinary tract pathogens. Digranes A; Dibb WL; Ostervold B Acta Pathol Microbiol Immunol Scand B; 1984 Apr; 92(2):101-6. PubMed ID: 6233841 [TBL] [Abstract][Full Text] [Related]
25. Tentative interpretive standards for agar disk diffusion antimicrobial susceptibility testing of cefoperazone. Thornsberry C; Barry AL; Jones RN; Baker CN; Badal RE J Clin Microbiol; 1982 May; 15(5):769-76. PubMed ID: 6212595 [TBL] [Abstract][Full Text] [Related]
26. The in-vitro activity of ciprofloxacin compared with that of norfloxacin and nalidixic acid. King A; Shannon K; Phillips I J Antimicrob Chemother; 1984 Apr; 13(4):325-31. PubMed ID: 6233249 [TBL] [Abstract][Full Text] [Related]
27. In vitro activity of the aryl-fluoroquinolones A-56619 and A-56620 and evaluation of disk susceptibility tests. Barry AL; Jones RN; Thornsberry C; Ayers LW; Gavan TL; Gerlach EH Eur J Clin Microbiol; 1986 Feb; 5(1):18-22. PubMed ID: 2938944 [TBL] [Abstract][Full Text] [Related]
28. Comparative antimicrobial activity of enoxacin, ciprofloxacin, amifloxacin, norfloxacin and ofloxacin against 177 bacterial isolates. Bassey CM; Baltch AL; Smith RP J Antimicrob Chemother; 1986 May; 17(5):623-8. PubMed ID: 2941401 [TBL] [Abstract][Full Text] [Related]
29. Norfloxacin, a fluoroquinolone antibacterial agent. Classification, mechanism of action, and in vitro activity. Goldstein EJ Am J Med; 1987 Jun; 82(6B):3-17. PubMed ID: 3111257 [TBL] [Abstract][Full Text] [Related]
30. Evaluation of teicoplanin and vancomycin disk susceptibility tests. Barry AL; Thornsberry C; Jones RN J Clin Microbiol; 1986 Jan; 23(1):100-3. PubMed ID: 2939101 [TBL] [Abstract][Full Text] [Related]
31. In vitro antibacterial activity of norfloxacin and other agents against ocular pathogens. Shungu DL; Tutlane VK; Weinberg E; Gadebusch HH Chemotherapy; 1985; 31(2):112-8. PubMed ID: 3157551 [TBL] [Abstract][Full Text] [Related]
33. Multicenter evaluation of the proposed quality control limits and interpretive zone standards for in vitro susceptibility testing with norfloxacin. Shungu DL; Tutlane V; Gadebusch HH J Clin Microbiol; 1983 Oct; 18(4):988-91. PubMed ID: 6226677 [TBL] [Abstract][Full Text] [Related]
34. 3-0-demethyl fortimicin A: in vitro activity and interpretive zone standards for disk diffusion susceptibility tests. Barry AL; Jones RN; Thornsberry C; Gavan TL; Gerlach EH; Sommer HM Eur J Clin Microbiol; 1984 Dec; 3(6):531-7. PubMed ID: 6441709 [TBL] [Abstract][Full Text] [Related]
35. In vitro activity of MK-0366 against clinical urinary pathogens including gentamicin-resistant Pseudomonas aeruginosa. Downs J; Andriole VT; Ryan JL Antimicrob Agents Chemother; 1982 Apr; 21(4):670-2. PubMed ID: 6211142 [TBL] [Abstract][Full Text] [Related]
36. Study of the in vitro activity of norfloxacin and other drugs on amoxicillin-resistant uropathogenic isolates. Piccolomini R; Allocati N; Catamo G Chemioterapia; 1984 Jun; 3(3):167-72. PubMed ID: 6241505 [TBL] [Abstract][Full Text] [Related]
37. In vitro activity of ciprofloxacin, norfloxacin and nalidixic acid. Bauernfeind A; Petermüller C Eur J Clin Microbiol; 1983 Apr; 2(2):111-5. PubMed ID: 6222896 [TBL] [Abstract][Full Text] [Related]
38. In vitro activity of enoxacin compared with norfloxacin and amikacin. van der Auwera P; de Moor G; Lacroix G; Mambour A; Rossion N; Schuyteneer F Eur J Clin Microbiol; 1985 Feb; 4(1):55-8. PubMed ID: 3157568 [TBL] [Abstract][Full Text] [Related]
39. In vitro antibacterial activity of three new quinolone derivatives: rosoxacin, norfloxacin, pefloxacin. Husson MO; Izard D; Leclerc H Zentralbl Bakteriol Mikrobiol Hyg A; 1984 Dec; 258(2-3):283-6. PubMed ID: 6241772 [TBL] [Abstract][Full Text] [Related]
40. Reevaluations of disk diffusion susceptibility testing interpretive criteria for lomefloxacin and norfloxacin using fluoroquinolone-resistant isolates. Cormican MG; Jones RN Diagn Microbiol Infect Dis; 1995 Apr; 21(4):227-30. PubMed ID: 7554807 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]